HIGHLIGHTS
- Who: GSK- et al. from the Queen Mary University of London, United Kingdom have published the Article: Tumor microenvironment- modulating oncolytic adenovirus combined with GSK-3 b inhibitor enhances antitumor immune response against bladder cancer, in the Journal: (JOURNAL)
SUMMARY
Briefly, cancer-specific viral_replication and subsequent cytolysis of tumor cells by oAd release tumor-specific antigens and dangerassociated signaling molecules that promote tumor-specific immune_response. Arming the oAd with immune-stimulatory therapeutic genes, like cytokines and chemokines, further potentiates the antitumor immune_response mediated by the virus via exponential amplification of transgene products in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.